XFORHIGH SIGNALFINANCIAL10-K

X4 Pharmaceuticals executed a 1-for-30 reverse stock split and experienced a substantial increase in total assets alongside meaningfully improved operating cash flow performance.

The reverse stock split suggests the company was addressing compliance issues with exchange listing requirements, typically indicating significant stock price deterioration. However, the company's financial position appears to have strengthened considerably, with total assets nearly doubling and operating cash flow losses improving by over one-third, suggesting potential access to new funding or other balance sheet improvements.

Comparing 2026-03-17 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

The company's balance sheet expanded substantially with total assets nearly doubling to $290.5M while total liabilities declined 16.2% to $104.2M, indicating a significantly strengthened financial position. Operating cash flow losses improved meaningfully from -$130.9M to -$85.6M, though R&D expenses declined modestly by 10.9% to $72.7M. The overall picture suggests the company secured substantial new funding or other capital infusion that has dramatically improved its balance sheet strength while reducing cash burn, though the reverse stock split indicates previous equity value deterioration.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+98.3%
$146.4M→$290.5M

Asset base grew 98.3% — expansion through organic growth, acquisitions, or capital deployment.

Accounts Receivable
Balance Sheet
-46.4%
$1.1M→$573K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Interest Expense
P&L
+44.7%
$4.0M→$5.8M

Interest expense surged 44.7% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
+34.6%
-$130.9M→-$85.6M

Operating cash flow surged 34.6% — exceptional cash generation, highest quality earnings signal.

Current Liabilities
Balance Sheet
-21.7%
$32.9M→$25.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-16.2%
$124.3M→$104.2M

Liabilities reduced 16.2% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-10.9%
$81.6M→$72.7M

R&D spending cut 10.9% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-26
ADDED
Independent Registered Public Accounting Firm PricewaterhouseCoopers LLP Boston, Massachusetts, US Firm ID 238 As of March 12, 2026, the registrant had 90,919,696 shares of common stock, $0.001 par value per share, outstanding.
Form 10-K Summary 84 EXPLANATORY NOTE On April 28, 2025, X4 Pharmaceuticals, Inc.
(the Company ), effected a 1-for-30 reverse stock split of its common stock (the Reverse Stock Split ).
Unless otherwise noted, all references to common stock share and per share amounts in this Annual Report on Form 10-K have been retroactively adjusted to reflect the Reverse Stock Split.
See Note 14, Common Stock and Preferred Stock of the consolidated financial statements for a description of the Reverse Stock Split.
+7 more — sign up free →
REMOVED
7262(b)) by the registered public accounting firm that prepared or issued its audit report.
On June 30, 2024, the aggregate market value of the registrant s voting common stock held by non-affiliates of the registrant was approximately $ 96 million based upon the closing sale price on the Nasdaq Capital Market reported on June 30, 2024.
Independent Registered Public Accounting Firm PricewaterhouseCoopers LLP Boston, Massachusetts, US Firm ID 238 As of March 20, 2025, there were 173,662,376 shares of the registrant s common stock, $0.001 par value per share outstanding.
We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements.
These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled Risk Factors and elsewhere in this report, regarding, among other things: there can be no assurance that we will be able to regain compliance with Nasdaq s listing requirements.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →